The timing for the four-valent HPV vaccine is as follows: two months after the first injection and then again after six months, a total of three injections, lasting for about half a year. This vaccine is mainly for women aged 20 to 45 years old, and the targeted HPV viruses are types 6, 11, 16, and 18. After the professional HPV vaccine injection is completed and the required treatment process is finished, it is not necessarily that there will be no infection with the corresponding HPV virus from then on. It still requires regular cervical cancer screening, that is, TCT and HPV tests.

The four-valent HPV vaccine prevents HPV infection after vaccination. Therefore, it cannot prevent existing HPV infection or potential cervical cancer precancerous lesions. Therefore, it is still necessary to undergo relevant tests after the completion of vaccination.

The injection interval for the four-valent cervical cancer vaccine is as follows: after the first injection, the second and third injections are administered in the second and sixth months after the injection, respectively. When injecting the cervical cancer vaccine, patients should pay attention to possible swelling, pain at the injection site, or allergic reactions.

Since the four-valent vaccine is a protein, it does not eliminate the pathogenic bacteria. Therefore, if a patient is allergic to proteins, especially patients with allergic constitution, they may experience severe allergic symptoms. Therefore, after the injection, patients need to stay under observation for half an hour to one hour before leaving the injection site. In addition, during the period of cervical cancer vaccine injection, patients should take good contraceptive measures. If pregnancy is detected, the injection should be immediately stopped without induced abortion, and pregnancy can be resumed.

The interval between the four-valent HPV vaccine injections is as follows: the first and second injections are separated by three months, and the second and third injections are separated by six months. This vaccine is crucial for women aged 9 to 26 years old and can effectively prevent cervical, vulvar, vaginal, and anal cancers caused by HPV types 16 and 18. It can also prevent genital warts (condyloma acuminatum) caused by HPV types 6 and 11, as well as cervical epithelial cell carcinomas at stage I, II, and III caused by HPV types 6, 11, 16, and 18, and cervical in situ carcinoma.